![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » GTC BIOTHERAPEUTICS AND SCANCELL COLLABORATE ON SC101 ANTIBODY
GTC BIOTHERAPEUTICS AND SCANCELL COLLABORATE ON SC101 ANTIBODY
GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) and Scancell Limited ("Scancell") announced that they have signed a collaboration agreement to evaluate the expression of Scancell's SC101 anti-cancer monoclonal antibody (MAb) using GTC's transgenic production platform. Their agreement contemplates that both companies will work toward the establishment of a definitive agreement for the potential clinical development of SC101.
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050728005572&newsLang=en)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct